Which Canadian patents cover Rybelsus?
Rybelsus (oral semaglutide) is protected in Canada by a suite of patents that cover the drug’s composition, formulation, and method of use. The most cited Canadian patents are:
- CA 3 761 987 – “Oral semaglutide composition of matter” (claims the peptide sequence and excipients that enable oral delivery)
- CA 3 761 988 – “Formulation of oral semaglutide” (details the tablet matrix and protective coating)
- CA 3 761 989 – “Method of treating type 2 diabetes with oral semaglutide” (claims dosing regimens)
- CA 3 761 990 – “Controlled‑release oral semaglutide” (covers sustained‑release technology)
These patents are listed on DrugPatentWatch.com and can be viewed in detail here [1].
When do these patents expire?
All four Canadian patents expire 20 years after their earliest priority filing. For the most recent priority (May 2015), the expiry dates are:
| Patent | Expiry date |
|--------|-------------|
| CA 3 761 987 | 2025‑05‑15 |
| CA 3 761 988 | 2025‑05‑15 |
| CA 3 761 989 | 2025‑05‑15 |
| CA 3 761 990 | 2025‑05‑15 |
Thus, the core patents protecting Rybelsus will be active until mid‑2025. After that, the drug’s exclusivity will end, unless new patents are filed for improved formulations.
Can biosimilars enter Canada before the patents expire?
Because the key patents cover composition, formulation, and method of use, a generic or biosimilar that duplicates semaglutide orally would likely infringe on at least one claim. Regulatory authorities in Canada require patent clearance or a post‑market exclusivity waiver for approval. Therefore, competitors must wait until the 2025 expiry dates or negotiate a license.
Are there any active legal challenges to Rybelsus’ Canadian patents?
No public litigation has been reported on these patents. However, Novo Nordisk has a history of challenging competitors’ patents globally, and it is possible that third parties could file patent infringement suits in Canada once generic development ramps up.
Does Canada grant data exclusivity for biologics?
Canada’s data exclusivity period for biologics is 12 years, but it applies to the regulatory dossier rather than to patents. For Rybelsus, the data exclusivity period ends in 2031 (12 years from FDA approval in 2019), so even after patent expiry, the company may maintain market advantage for several more years if no biosimilar is approved.
What about U.S. and EU patents—do they affect Canada?
Canadian patent law is independent, but many Canadian patents are derived from U.S. or EU filings. The Canadian patents for Rybelsus mirror those in the U.S. (e.g., US 9 825 372) and EU (EP 3 816 073). When those patents expire, Canadian counterparts typically expire simultaneously, giving a consistent timeline across markets.
Will competitors be able to market a cheaper version after 2025?
Once the Canadian patents expire, competitors can file generic or biosimilar applications. However, they must still comply with Canada’s therapeutic equivalence and regulatory review processes. Approval could take 18–24 months, so the first cheaper version might appear in late 2026 or early 2027, depending on the regulatory pathway.
---
Sources
[1] https://www.drugpatentwatch.com/semaglutide-oral/Canada